July 1, 2026
The Nguoit Viet News wrote an article in Vietnamese on how hundreds of residents attended a free health fair at St. Columban Church. The Mobile Research Unit was at the event and had a record of 55 screenings while sharing the importance of brain health.
To read the article in Vietnamese from the outlet, visit:
GAP Experts Share Poster Presentations at Alzheimer’s Association International Conference (AAIC)
Washington D.C., July 9, 2026- The Global Alzheimer’s Platform Foundation®, (GAP) will have two poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC) being held in Londong July 12 through July 15. All posters are in the Exhibit Hall in Excel London, Royal Victoria Dock, 1 Western Gateway, London.
“A Comparison of Flortaucipir and MK6240 Tau PET Positivity Rates in the Bio-Hermes-002 study“
Who: Lammert Albers, Chief Commercial Officer, Global Alzheimer’s Platform Foundation
When: Sunday, July 12, 7:30 AM-4:15PM GMT
“Expanding clinical trial access to Underrepresented Populations in the U.S.: Findings from the Alzheimer’s Disease Pre-Screener Study”
Who: Irma Kurniawan¹*; Tamiko MaGee-Rodgers²*; Luisa Guglielmini³; Justin Ford²; Mia Chester²; Theo Christofides4; Enrique Gaspar¹; Kelly Coultes5; Christopher Lane4; Lisa Squassante¹; Nicola Maiorano¹; Julian Tillmann¹; Rosanna Tortelli¹; Ruth Croney4
¹ F. Hoffmann-La Roche Ltd, Basel, Switzerland; ² Global Alzheimer’s Platform Foundation, Washington, DC, USA; ³Genentech, Inc., South San Francisco, CA, USA; Roche Products Ltd, Welwyn Garden City, UK; Hoffmann-La Roche Ltd, Mississauga, ON, Canada. (*Joint first authors.)
When: Sunday, July 12, 7:30 AM-4:15PM GMT
GAP can arrange interviews surrounding the presentations and for more information on GAP, visit globalalzplatform.org/.
END
About GAP
The Global Alzheimer’s Platform Foundation® (GAP) is a person-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias
Washington D.C., July 8, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Taudia to the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse racial and ethnic populations, to generate data that may improve the prediction, detection, and diagnosis of Alzheimer’s disease and related dementias.
The Bio-Hermes-002 study collects data reflecting the performance of each biomarker in the study, or combination of biomarkers, to assess, diagnose or predict the presence of a variety of pathologies associated with Alzheimer’s Disease and related dementias including amyloid and tau in the brain – hallmark characteristics of Alzheimer’s disease.
“Taudia’s decision to join the growing list of collaborators in the Bio-Hermes-002 study adds yet another emerging leader in AD diagnostic tests,” said John Dwyer, President of GAP. “This new partnership will enhance our efforts to offer the field an armamentarium of cutting-edge solutions for more precisely identifying the pathologies fueling the progression of Alzheimer’s and related dementias. Expanding the field’s understanding of tau-focused biomarkers is critical, and we look forward to seeing Taudia’s impact on the future of diagnostic innovation.”
In Bio-Hermes-002, Taudia is bringing more tau-focused biomarkers to the study with the addition of BD pTau-217 and eMTBR-tau243, augmenting our robust database and building upon findings from Bio-Hermes-001. Taudia will be analyzing both plasma as well as CSF on those biomarkers.
“We are honored to partner with the Global Alzheimer’s Platform Foundation and contribute to the Bio-Hermes-002 study,” said Paul Hung, Ph.D., CEO of Taudia. “By evaluating novel blood-based biomarkers such as BD pTau-217 and eMTBR-tau243 in plasma and cerebrospinal fluid alongside imaging, digital assessments, and other neurological biomarkers, we aim to deepen the understanding of Alzheimer’s disease biology while advancing precise, accessible tools for disease detection and monitoring. Designed to plug directly into widely available molecular testing workflows, Taudia’s technology has the potential to expand global access while improving cost efficiency and throughput flexibility. Bio-Hermes-002 is the kind of collaboration needed to translate biomarker innovation into meaningful impact for patients, researchers, and drug developers.”
Taudia joins a long list of industry leaders who are partners in this study, including Biogen, Eli Lilly and Company, IXICO, and Roche along with other exceptional partners providing blood-based biomarker assessments or digital assessments for Bio-Hermes-002. To date, the partners include AINOSTICS, Alamar Biosciences, Beckman Coulter Diagnostics, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Fujirebio, iLoF, LifeArc, Linus Health, Lucent Diagnostics–a Quanterix brand, Sanofi, Siemens Healthineers, Spear Bio, and ViewMind.
For more information about the Bio-Hermes-002 study and how to participate, visit https://globalalzplatform.org/.
For immediate release:
Contact: [email protected]
About the Global Alzheimer’s Platform Foundation (GAP)
The international nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments and other neurological therapies with a commitment to lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting the use of state-of-the-art biomarker technology and inclusivity in research studies, as well as celebrating the citizen scientists who make research possible.
About Taudia
Taudia is a precision proteomics company developing highly sensitive and accessible blood-based tools for neurological disease research, detection, and monitoring. Its proprietary SPLASH™ technology integrates seamlessly into widely available molecular testing workflows, enabling ultrasensitive protein biomarker measurement with minimal sample input, scalable throughput, and lower capital and operating costs. Taudia is initially focused on advancing biomarker solutions for Alzheimer’s Disease and other neurodegenerative conditions. The company is headquartered in San Carlos, California. For more information, please visit Taudia’s website.
By:Ingrid Johansen, Date: July 7, 2026
A significant global research initiative is underway to develop a convenient blood test for diagnosing Alzheimer’s disease. The study focuses on three specific proteins linked to the condition, aiming to compare the efficacy of the test with current brain scans. If successful, this new test could offer a simpler alternative to existing diagnostic methods like scans, lumbar punctures, and spinal taps. Utilizing a plasma separation card, the finger prick test would leverage digital biomarkers to expedite Alzheimer’s diagnosis, potentially enabling earlier intervention at a lower cost.
The research is part of the Global Alzheimer’s Platform Foundation (GAP) Bio-Hermes-002 study, supported by the non-profit organization LifeArc. Nearly 883 out of the required 1,000 volunteers have already been enrolled from various sites in the UK, USA, and Canada. The participants include individuals at different stages of the disease, ranging from asymptomatic to mild cognitive impairment and mild to moderate Alzheimer’s.
Dr. Giovanna Lalli, Director of Strategy and Operations at LifeArc, emphasized the importance of developing accessible and affordable tests to combat Alzheimer’s disease effectively. She expressed optimism about the potential of a finger-prick blood test to improve patient access to early-stage disease treatments. John Dwyer, President of GAP, highlighted the transformative impact a simple blood test could have on diagnosis, noting the need for further refinement post-trial completion.
Prof Henrik Zetterberg, Lead of the Biomarker Factory at the UK Dementia Research Institute, stressed the significance of comparing the new test results against current diagnostic standards. If successful, the minimally invasive and cost-effective diagnostic method could revolutionize Alzheimer’s diagnosis and pave the way for enhanced detection of neurodegenerative conditions.
The research trial is set to conclude in 2028, with an estimated 944,000 dementia cases in the UK and around seven million in the US. Alzheimer’s, affecting six in 10 dementia patients, manifests with memory loss, reasoning challenges, and language difficulties as initial symptoms. Recent analysis by Alzheimer’s Research UK revealed an increase in dementia-related deaths in the UK, making it the leading cause of mortality in the country.
By opting for Daily Mirror as a ‘Preferred Source’ on Google News, users can access valuable news content conveniently.
Washington D.C., July 1, 2026- Elevance Health, formerly Anthem Inc., updated their medical policy, to allow for blood-based biomarker testing for the detection and diagnosis of Alzheimer’s disease, making Elevance Health one of the first major payors to outline coverage criteria.
GAP President John Dwyer said, “GAP applauds the decision by Elevance Health to explicitly endorse the use of blood-based biomarkers as a tool to assist in the diagnosis or guide the clinical management of Alzheimer disease. As the first major payor to establish a coverage policy for blood-based biomarkers as an appropriate element of the diagnostic process for Alzheimer’s disease, this marks an important milestone for expanding access for patients and enhancing the quality of care they receive. By improving access to an earlier and more reliable diagnostic program, Elevance Health is empowering patients and their physicians to use the best tools to make informed decisions about treatment, care planning, and participation in clinical research. It also represents meaningful progress for the field by accelerating the adoption of diagnostics that will improve the quality of care for people at risk for Alzheimer’s disease.”
About the Global Alzheimer’s Platform Foundation (GAP)
The international nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments and other neurological therapies with a commitment to lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting the use of state-of-the-art biomarker technology and inclusivity in research studies, as well as celebrating the citizen scientists who make research possible.
GARDEN GROVE, California (NV) – Hàng tr?m c? dân tham d? “H?i Ch? S?c Kh?e và Ngu?n L?c C?ng ??ng” do Hi?p H?i Ph? N? M? G?c Á Orange County (AAWA-OC) t? ch?c t?i nhà th? St. Columban, Garden Grove, hôm Th? B?y, 27 Tháng Sáu, v?i nhi?u d?ch v? khám s?c kh?e mi?n phí, t? v?n y t? và k?t n?i các ngu?n h? tr? dành cho c?ng ??ng.
H?i ch? kéo dài t? 9 gi? sáng ??n 3 gi? chi?u, v?i s? góp m?t c?a các bác s?, chuyên gia y t?, sinh viên nhi?u tr??ng ??i h?c, tình nguy?n viên, và các t? ch?c c?ng ??ng cùng tham gia ph?c v? ng??i dân.
Ngay t? sáng, nhi?u ng??i ??n ki?m tra huy?t áp, ???ng huy?t, nh?p tim, n?ng ?? oxy trong máu, ?o chi?u cao, cân n?ng, ch? s? BMI, m?t ?? x??ng, ?ánh giá trí nh?, ??ng th?i ???c t? v?n v? Medicare, s? d?ng thu?c, ?i?u tr? n?n ch?nh x??ng (chiropractic), massage tr? li?u, và các d?ch v? xã h?i.
Ông An Phan, c? dân thành ph? Sylmar (Los Angeles County), cho bi?t ông lái xe h?n 50 d?m cùng v? ??n tham d? h?i ch?. Sau khi th?c hi?n các b??c sàng l?c s?c kh?e, ông cho bi?t các ch? s? nhìn chung ??u t?t, ngo?i tr? tình tr?ng m? máu cao ?ang ???c bác s? gia ?ình theo dõi.
“?ây là ch??ng trình r?t ý ngh?a vì v?a giúp ng??i dân ki?m tra s?c kh?e ban ??u, v?a t?o ?i?u ki?n ?? các em sinh viên ngành y th?c hành và ph?c v? c?ng ??ng. N?u k?t qu? sàng l?c có d?u hi?u b?t th??ng thì m?i ng??i nên ??n g?p bác s? ?? ???c khám và t? v?n thêm,” ông nói.
Theo Ti?n S? ?? Ng?c Hà, sáng l?p viên kiêm ch? t?ch AAWA-OC, ban t? ch?c dành g?n m?t n?m r??i chu?n b? cho h?i ch? v?i m?c tiêu k?t n?i các tr??ng ??i h?c, chuyên gia y t?, lãnh ??o c?ng ??ng, sinh viên, và tình nguy?n viên cùng chung tay ph?c v? ng??i dân. ?ây c?ng là c? h?i ?? sinh viên áp d?ng ki?n th?c chuyên môn vào th?c t? thông qua các ho?t ??ng ch?m sóc s?c kh?e c?ng ??ng.
“S? m?nh c?a AAWA-OC là giúp m?i ng??i d? dàng ti?p c?n thông tin s?c kh?e, các d?ch v? ch?m sóc phòng ng?a và nh?ng ngu?n h? tr? ?áng tin c?y trong c?ng ??ng. Chúng tôi mong mu?n giúp m?i cá nhân và gia ?ình ch? ??ng ch?m sóc s?c kh?e, ??ng th?i cùng nhau xây d?ng m?t c?ng ??ng kh?e m?nh h?n,” bà nóiNgoài các khu v?c khám sàng l?c, ng??i dân còn ???c g?p tr?c ti?p các bác s? ?? gi?i ?áp nh?ng th?c m?c v? ch?m sóc s?c kh?e, b?nh Alzheimer’s, Medicare, và các ngu?n h? tr? dành cho ng??i cao niên.
Bác S? Qu?nh Ki?u, thu?c VM Medical Group, cho bi?t nhi?u gia ?ình g?p khó kh?n khi ti?p c?n bác s? chuyên khoa do th?i gian ch? ??i kéo dài, ??c bi?t v?i tr? ch?m phát tri?n ho?c g?p các v?n ?? v? tâm lý và hành vi.
Theo bà, vi?c can thi?p s?m có ý ngh?a r?t quan tr?ng ??i v?i s? phát tri?n c?a tr? em. Nh?ng h?i ch? s?c kh?e nh? th? này giúp ng??i dân ti?p c?n nhanh h?n v?i các d?ch v? sàng l?c, t? v?n và nhi?u d?ch v? mà không ph?i phòng m?ch nào c?ng có.
Trong khi ?ó, Bác S? D?ng Tr?nh, giám ??c y khoa Healthy Brain Clinic kiêm thành viên h?i ??ng qu?n tr? Alzheimer’s Orange County, l?u ý b?nh Alzheimer’s v?n th??ng ???c phát hi?n mu?n trong c?ng ??ng ng??i Vi?t vì nhi?u gia ?ình xem m?t trí nh? là d?u hi?u bình th??ng c?a tu?i già ho?c ng?i ??a ng??i thân ?i khám.
Theo bác s?, vi?c phát hi?n s?m giúp ng??i b?nh có c? h?i làm ch?m ti?n tri?n c?a b?nh thông qua ch? ?? dinh d??ng, t?p th? d?c, ng? ?? gi?c, và duy trì các ho?t ??ng trí não. Nh?ng d?u hi?u ban ??u có th? ch? là quên tên, quên t? ng?, quên lý do b??c vào m?t c?n phòng ho?c th??ng xuyên ?? quên ?? v?t.
??ng ngh? m?t trí nh? là chuy?n bình th??ng c?a tu?i già. Càng phát hi?n s?m, chúng ta càng có nhi?u c? h?i b?o v? các t? bào não,” ông nh?n m?nh.
Cô Tina Tr?n, m?t tình nguy?n viên t?i h?i ch?, cho bi?t cô tham gia các ho?t ??ng ph?c v? c?ng ??ng t? khi còn là sinh viên v?i mong mu?n giúp c?ng ??ng ng??i Vi?t kh?e m?nh h?n.
Theo cô, ?i?u cô yêu thích nh?t là giúp ng??i l?n tu?i hi?u rõ ý ngh?a c?a các ch? s? s?c kh?e nh? huy?t áp và ???ng huy?t ?? bi?t cách ch?m sóc b?n thân.
Cô k? m?t k? ni?m ?áng nh? là t?ng phiên d?ch cho m?t thai ph? ch? nói ti?ng Vi?t trong l?n khám thai ??u tiên.
“?i?u ?ó khi?n tôi nh? ??n m? mình khi m?i sang M? c?ng g?p rào c?n ngôn ng?. Tôi hy v?ng s? có thêm nhi?u b?n tr? tham gia tình nguy?n ?? giúp nh?ng ng??i Vi?t g?p hoàn c?nh t??ng t?,” cô nói.
Ông Minh T?ng, ??i di?n Astiva Health, cho bi?t công ty ti?p t?c ??ng hành cùng AAWA-OC n?m th? hai liên ti?p nh?m cung c?p thông tin v? Medicare và các quy?n l?i ch?m sóc s?c kh?e cho ng??i cao niên.
??i di?n Becker Law Group, ông Gavin Fang, c?ng chia s? nh?ng thông tin liên quan ??n v? rò r? hóa ch?t t?i Garden Grove, khuy?n ngh? nh?ng c? dân b? ?nh h??ng nên theo dõi s?c kh?e, l?u gi? hóa ??n, h? s? y t?, và các b?ng ch?ng liên quan, ??ng th?i tìm hi?u các quy?n l?i pháp lý n?u phát sinh thi?t h?i v? s?c kh?e ho?c tài s?n. [?.d.]
John Dwyer, the President of the Global Alzheimer’s Platform Foundation (GAP) joins TrialSiteNews to discuss a collaboration and partnership with Circular Genomics. The partnership will analyze blood test samples to investigate the potential for circular RNA biomarkers to assist in the diagnosis & treatment of Alzheimer’s Disease. Topics covered:
Press Release: https://globalalzplatform.org/2026/05…
Story by Amy Scherzer, Bay Correspondent
Tearful yet joyful, the annual Inspire, Imagine & Hope Gala honored Tampa neurologist Dr. Susan Steen for her 40-plus years advancing brain health education and leading clinical trials for Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. Gala co-chairs Lyle Fogarty and Dr. Shannon Moroney shared the personal impact of Alzheimer’s on their families, noting that Florida has the nation’s second-highest number of seniors living with the disease. Tracy and Tom Hayes offered insights from both sides of the illness — first losing her mother and now facing Tom’s diagnosis together. The March 27 gala, “Making Waves for a Cure,” netted $780,000 in support of the Alzheimer’s Association’s Florida Gulf Coast chapter.
For photos from the Gala visit: https://www.tampabay.com/life-culture/bay-magazine/2026/06/12/alzheimers-association-florida-gulf-coast-chapter-gala/
Free Memory Screenings Offered Across the Country during Alzheimer’s and Brain Awareness Month
WASHINGTON, DC (June 4, 2026)- Alzheimer’s research sites across the country are recognizing Alzheimer’s and Brain Awareness Month by offering free memory screenings for adults age 55 and older. Throughout June, researchers are raising awareness about brain health and the importance of learning about ways to mitigate risk factors related to dementia and how to talk with doctors about memory concerns and opportunities available to them.
While awareness of healthy lifestyle habits is widespread, many Americans do not realize their role in reducing dementia risk. Although three out of four Americans recognize the value of these habits for brain health, fewer than half understand that they may also help lower the likelihood of developing dementia.[1] The month-long observance is an opportunity to encourage conversations about brain health, promote early detection, and connect individuals with resources that can support cognitive wellness throughout aging.
Participating sites for no cost memory screens include:
Northeast
Southeast
Midwest
South
West
Canada
Memory screenings in a private setting can be scheduled by appointment at each participating site. Following the scheduled assessment, individuals may meet one-on-one with a healthcare professional to review results and discuss any questions or concerns. While a memory assessment is not a diagnosis, it can guide individuals toward appropriate next steps.
Early detection of memory problems can provide access to more intervention options and improve quality of life. It may also help individuals learn whether they are eligible to participate in clinical trials focusing on slowing the progression of memory disorders.
For more information on services, including memory screenings, please contact the site nearest to you directly.
For Immediate Release:
For local media interested in highlighting a community research site, contact [email protected] for interviews.
About the Global Alzheimer’s Platform Foundation (GAP):
The international nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments and other neurological therapies with a commitment to lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting the use of state-of-the-art biomarker technology and inclusivity in research studies, as well as celebrating the citizen scientists who make research possible.
[1] https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf
Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data
Washington D.C., May 28, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Circular Genomics, a biotechnology company revolutionizing neurological and psychiatric precision medicine, access to analyze Bio-Hermes-001 samples to investigate the potential for circular RNA biomarkers to transform diagnosis, prognosis and treatment of Alzheimer’s Disease.
“We are pleased to collaborate with Circular Genomics and are encouraged by the potential for this leader in biotechnology to analyze Bio-Hermes-001 data to further the exploration of the potential for circular RNA biomarkers,” said John Dwyer, the President of GAP. “I look forward to seeing what stems from this unique partnership and to our work improving the future of Alzheimer’s research.”
“Circular RNA biomarkers offer a unique window into the molecular complexity of Alzheimer’s disease,” said Paul Sargeant, CEO of Circular Genomics. “Our platform captures disease-relevant biological signals that complement protein-based markers, providing deeper insights into neurodegenerative disease mechanisms. The Bio-Hermes-001 cohort, with its exceptional diversity and comprehensive biomarker characterization, represents an ideal setting to validate the clinical utility of circRNA signatures and advance our understanding of how these stable, brain-derived, and blood-accessible molecules can inform precision medicine approaches for Alzheimer’s disease and related dementias.”
The Bio-Hermes-001 study compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays in over 1,000 community-based participants throughout the US. The study revealed a strong correlation between several blood tests with the presence of amyloid plaques in the brain, a diagnostic hallmark of Alzheimer’s disease. This relationship was demonstrated across the entire study population including the 24% percent of Bio-Hermes participants from African American, Latino and other traditionally underrepresented communities, an unprecedented level of diversity.
For more information about the Bio-Hermes-001 study visit https://globalalzplatform.org.
For immediate release:
Contact: [email protected]
About the Global Alzheimer’s Platform Foundation (GAP):
The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.
About Circular Genomics
Circular Genomics is a biotechnology company pioneering circular RNA-based precision medicine for neurological and psychiatric disorders. The company is advancing a proprietary platform that leverages the unique stability and biological relevance of brain-derived circular RNAs to develop blood-based diagnostics for neurodegenerative diseases, including Alzheimer’s disease. By capturing disease-specific molecular signatures in blood, Circular Genomics aims to enable earlier detection, improved patient stratification, and deeper mechanistic understanding of complex brain disorders — ultimately advancing personalized treatment strategies for patients and families affected by neurological and psychiatric conditions.